Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8637054 | THEA PHARMA | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives |
Jul, 2031
(7 years from now) |
Market Authorisation Date: 13 December, 2022
Treatment: Topical treatment of ocular hypertension and glaucoma
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9539262 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Oct, 2028
(4 years from now) | |
US9629852 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Sep, 2029
(5 years from now) |
Market Authorisation Date: 12 September, 2018
Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Dosage: EMULSION;OPHTHALMIC